← Back to Screener
SpyGlass Pharma, Inc. Common Stock (SGP)
Price$18.78
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (4W)-19.77%
VGM Score35.92
Market Capitalization$619.17M
All Metrics
Book Value / Share (Quarterly)$7.48
Indicated Dividend (Annual)$0.00
Price vs S&P 500 (YTD)-35.66%
EPS (TTM)$-2.78
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-2.78
EPS (Annual)$-2.50
ROI (Annual)-75.44%
Cash / Share (Quarterly)$7.51
ROA (Last FY)-68.82%
EBITD / Share (TTM)$-2.96
Cash Flow / Share (Annual)$-2.07
P/B Ratio2.48x
P/B Ratio (Quarterly)3.46x
Net Income / Employee (Annual)$-1,226,700
EPS Incl Extra (Annual)$-2.50
Current Ratio (Annual)12.67x
Quick Ratio (Quarterly)37.75x
3-Month Avg Trading Volume0.11M
Revenue / Employee (TTM)$0
52-Week High$32.44
EPS Excl Extra (Annual)$-2.50
Quick Ratio (Annual)12.57x
13-Week Price Return-28.92%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)38.00x
Enterprise Value$380.27M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$3.37
3-Month Return Std Dev67.86%
Net Income / Employee (TTM)$-1,235,100
ROE (Last FY)-75.44%
EPS Basic Excl Extra (Annual)$-2.50
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.78
Revenue / Share (Annual)$0.00
Year-to-Date Return-28.86%
5-Day Price Return2.51%
EPS Normalized (Annual)$-2.50
Month-to-Date Return-2.49%
EBITD / Share (Annual)$-2.58
EPS Basic Excl Extra (TTM)$-2.78
Price vs S&P 500 (13W)-37.17%
Beta1.35x
Revenue / Share (TTM)$0.00
52-Week Low$17.60
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.69est. -0.51
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
4.44
4.44
4.44
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SGPSpyGlass Pharma, Inc. Common Stock | — | — | D | $18.78 |
| SYKStryker Corporation | C | C | C | $305.66 |
| MMM3M Company | C | F | C | $153.76 |
| BSXBoston Scientific Corp. | C | B | D | $48.55 |
| MDLNMedline Inc. Class A common stock | C | D | D | $33.61 |
| BDXBecton, Dickinson and Co. | B | C | C | $151.16 |
| RMDResMed Inc. | C | B | C | $196.04 |
| DXCMDexCom, Inc. | C | B | C | $72.86 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $314.50 |
| SOLVSolventum Corporation | C | D | B | $81.01 |
| PENPenumbra, Inc. | F | C | B | $320.53 |
About
SpyGlass Pharma is a late-stage biopharmaceutical company developing long-acting drug delivery systems for chronic eye conditions. The company is advancing two programs: the BIM-IOL System, which delivers glaucoma treatment during cataract surgery, and the BIM-DRS for glaucoma patients not undergoing surgery. Both programs leverage sustained drug delivery of approved medicines to address unmet treatment needs in ophthalmology.